MRN ERN Banner
microRNA as Biomarkers and Diagnostic 2016 - マイクロRNAバイオマーカー・診断技術学会 2016年 -
2016年4月4日 - 2016年4月5日
米国、マサチューセッツ州、ケンブリッジ、ハイアット リージェンシー ケンブリッジ
microRNA as Biomarkers and Diagnostics

近年の研究により、微小なノンコーディングRNAであるマイクロRNAは、細胞過程の主要制御因子となっていることが判明しており、発現パターンは、診断を行ったり、予後や治療反応を調べたりするためのバイオマーカーとしての可能性を示唆しています。Cambridge Healthtech Institute (CHI) 主催の第12回microRNA as Biomarkers and Diagnosticsでは、疾病の早期発見、がんの進行と治療応答の監視、免疫の把握といった目的でのマイクロRNA利用に関する最新の研究が紹介されます。また、将来の個別化医療に及ぼす影響、マイクロRNAバイオマーカーを臨床現場で活用するうえでの問題なども議論されます。

1日目 | 2日目


推奨するディナーショートコース *

4月3日 (日) 、17:00〜20:00
(ショートコース1) データの正規化にまつわる課題と対策

* 別途参加登録が必要です。


4月4日 (月)

7:00 学会の登録手続き、コーヒー

8:00 当学会のディレクターによる歓迎の挨拶


非侵襲的な診断と予測を可能にするバイオマーカーとしてのマイクロRNA

8:10 議長による開会の挨拶

Ajay Goel, Ph.D., Professor and Director, Center for Gastrointestinal Research, and Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute, Baylor University Medical Center

8:15 結腸直腸がんのノンコーディングRNAバイオマーカー

Ajay Goel, Ph.D., Professor and Director, Center for Gastrointestinal Research, and Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute, Baylor University Medical Center

Non-coding RNAs (ncRNAs) are emerging as important regulators of gene expression in cancer. Overexpression of specific non-coding RNAs (including microRNAs, snoRNAs, piRNAs and circular RNAs) has been linked to the stepwise disease progression in colorectal cancer (CRC). Given their cancer-specific pattern of expression, remarkable stability and presence in blood and other body fluids, ncRNAs are considered to be highly promising cancer biomarkers. Accumulating evidence firmly supports the existence of unique 'ncRNA signatures' that can not only facilitate earlier detection of the tumor, but can also assist in predicting disease recurrence and therapeutic outcome to current treatment regimens.

8:45 腎臓病に対応する非侵襲的なマイクロRNAバイオマーカー

Vishal S. Vaidya, Ph.D., Associate Professor, Medicine & Environmental Health, Harvard Medical School, Harvard T.H. Chan School of Public Health, Brigham and Women's Hospital

MiRNAs play a critical regulatory role in health and disease. Abundant expression, lower complexity, stability in various detection matrices and amplifiable signals are qualities that make extracellular miRNAs attractive as biomarkers reflecting a variety of pathophysiological conditions. We highlight the transformative potential of miRNAs as mechanistic biomarkers in translational medicine.

9:15 心臓病と機能障害での血中循環マイクロRNA

Yuri D'Alessandra, Ph.D., Senior Researcher, Immunology and Functional Genomics Unit, Centro Cardiologico Monzino

Circulating microRNAs are emerging as biomarkers of several heart-related diseases. We have conducted studies encompassing many different cardiac maladies and identified specific circulating miRNAs as potential diagnostic markers.

9:45 スポンサー提供のプレゼンテーション (講演者を募集しています)

10:15 展示会ホールでの休憩、ポスター発表の見学


組織と生物流体に含まれるマイクロRNAバイオマーカーの識別

10:45 性特異性、集団特異性、人種特異性の調節ノンコーディングRNA

Isidore Rigoutsos, Ph.D., Professor and Director, Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University

By analyzing human transcriptomes from different people and different tissues, we found two types of short regulatory RNAs that are produced constitutively, and demonstrated that their composition and abundances depend on a person's gender, population and race as well as on tissue, tissue state, and disease subtype. The first type of short RNAs comprises numerous isoforms of mature microRNAs (miRNAs) that arise from virtually every known miRNA precursor. The second type of short RNAs comprises numerous fragments of mature transfer RNAs (tRNAs). We also discovered a novel category of tRNA fragments, the i-tRFs, which are wholly internal to the span of the mature tRNA and contribute much of the observed difference across individuals and tissues. The findings have direct implications for Precision Medicine and our understanding of the mechanisms underlying the onset and progression of disease.

11:15 膠芽腫の残存と治療反応を予測するマイクロRNAシグネチャーの識別

Sean Lawler, Ph.D., Assistant Professor, Neurosurgery, Brigham & Women's Hospital, Harvard Medical School

11:45 腎疾患でのマイクロRNAシグネチャー:組織と尿のデータセットのメタ分析

Christos Argyropoulos, M.D., Ph.D., MS, Assistant Professor, Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine

MicroRNA (miRNA) are negative regulators of gene translation and an emerging biomarker in a wide variety of diseases. Little is known about the ability of miRNA to correctly classify patients with clinically significant renal pathology. We undertook a meta-analysis of miRNA profiles from clinical samples (biopsy or biofluid) in Gene Expression Omnibus. MiRNA profiles from 31 urine samples and 117 biopsy samples were available for analyses. A short signature of 19 miRNAs achieved a superior classification performance for renal pathology (cross-validated AUC 0.96).

12:15 プレゼンテーションを聞きながらの昼食会または各自で昼食


医薬品開発におけるマイクロRNA

1:25 議長の発言

Bing-Hua Jiang, Ph.D., Professor, Pathology, Anatomy and Cell Biology, Thomas Jefferson University

1:30 糸球体障害の尿中マイクロRNAバイオマーカーの識別

Rounak Nassirpour, Ph.D., Principal Scientist, Biomarkers Laboratory, Drug Safety R&D, Pfizer

Recent studies have reported significant levels of microRNAs in a variety of body fluids, raising the possibility that microRNAs could serve as useful biomarkers. Here we describe urinary microRNA expression alterations in preclinical models of kidney injury. The microRNAs identified may be promising translatable preclinical urinary biomarkers for drug-induced glomerular injury.

2:00 薬物安全性を高めるための損傷バイオマーカーとして機能する非侵襲的マイクロRNAの評価

Xi Yang, Ph.D., Research Biologist, Systems Biology, National Center for Toxicological Research, FDA

Drug-induced liver injury is an important regulatory concern and a common reason for drug withdrawal. Acetaminophen (APAP) overdose is a major cause of acute liver failure in the Western world. Sensitive and specific biomarkers are required as diagnosis tools in the clinic and in screening assays during drug development stages. In our recent study, urinary miRNAs' potential as diagnostic biomarkers has been explored.

2:30 マイクロRNAを利用した肺腫瘍サブタイプと予測される治療反応との差動シグナリングの把握

Molly A. Taylor, Ph.D., Senior Scientist, AstraZeneca

We have classified three novel subtypes of lung squamous cell carcinoma that each have unique microRNA expression and therapeutic response profiles. Combined analysis of activated pathways and microRNA promoters has identified transcription factors driven by activated pathways that drive differences in microRNA expression. Overall, these microRNAs and transcription factors may function as biomarkers of pathway activation and aid in distinguishing patient subtypes to predict response to therapy.

3:00 展示会ホールでの休憩、ポスター発表の見学

3:30 肝臓疾患の反映としての無細胞循環マイクロRNA

Steven Lockton, Ph.D., Senior Scientist, microMarkers, Regulus Therapeutics

MicroRNAs are stable in circulation and can be dysregulated with disease. Because microRNA expression is often organ-specific, cell-free circulating microRNA expression often reflects the diseased organ's pathophysiology. To map microRNAs to organs we profiled microRNA expression in mouse tissues. In a transgenic mouse model of hepatocellular carcinoma this serum reflection of liver distress was clearly demonstrated upon inducing HRAS. Similarly, in HCV-infected patients, aberrant serum microRNA expression was restored to a healthy-like state after treatment.

4:00 がんのマイクロRNAと治療薬耐性

Bing-Hua Jiang, Ph.D., Professor, Pathology, Anatomy and Cell Biology, Thomas Jefferson University

We initially demonstrated that PI3K and AKT play an important role in tumor angiogenesis. We found recently that reactive oxygen species (ROS) levels are increased in ovarian, prostate and breast cancer cells; and are involved in activating PI3K/AKT and HER2/HER3 signaling and suppressing several key microRNAs for regulating cancer development, drug resistance, tumor growth and angiogenesis. We found that microRNA dysregulations regulate tumor growth, angiogenesis and drug resistance in several kinds of human cancers. To understand the potential link of ROS and microRNA dysregulations, we showed that ROS can suppress a number of microRNA expression through DNA methylation for inducing some pro-oncogene expression such as HER2/HER3. In addition, we find that miRNA depression is regulated by DNA methylation and transcriptional activation. MiRNA dysregulation is involved in cancer development, autophagy and therapeutic resistance.

4:30 スポンサー提供のプレゼンテーション (講演者を募集しています)

5:00 展示会ホールでの歓迎レセプション、ポスター発表の見学

6:00 ショートコースの登録手続き


推奨するディナーショートコース *

4月4日 (月) 、18:15〜21:15
(ショートコース2) マイクロRNAベースの治療法

* 別途参加登録が必要です。


1日目 | 2日目

4月5日 (火)

7:30 朝食をとりながらのグループ討論

Roundtable discussion are interactive, topic-specific discussions hosted by expert moderators and open to all attendees. These session provide a forum for discussing key issues.

  • Topic 1: Targeting of microRNAs for Therapeutics

    Moderator: Amy K. Patick, Ph.D., Principal, Patick Pharmaceutical and Scientific Consulting

  • Topic 2: Next-Generation Sequencing

    Moderator: Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

  • Topic 3: miRNA as Cancer Biomarkers and Related Issues

    Moderator: Jingfang Ju, Ph.D., Associate Professor and Co-Director, Translational Research, Pathology, Stony Brook University

  • Topic 4: miRNAs and Exosomes

    Moderator: John Chevillet, Ph.D., Principal Scientist, N-of-One



NGSの課題

8:25 議長の発言

Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

8:30 次世代シーケンシング (NGS) を利用した人体病理学における新たな血液感染性マイクロRNAの発見

Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

Although over 2,500 mature human miRNAs are known there is still a race for novel markers. Screening of blood cell fractions using NGS is a reasonable approach for discovering such minimally-invasive disease markers. With NGS as a high-throughput technique, however, a significant number of false positive biomarker candidates is reported. We present a complete pipeline: efficient discovery of novel miRNAs, filtering of false positives, and validation. The performance of the novel pipeline is demonstrated using neurological diseases as well as lung cancer.

9:00 肺がん検出に有効な気管支上皮でのマイクロRNA発現

Ana Brandusa Pavel, Ph.D., Researcher, Computational Biomedicine, Boston University School of Medicine

Using bronchial brushings from current and former smokers undergoing bronchoscopy for suspect lung cancer, we profiled microRNA expression via small RNAseq on the Illumina HiSeq 2000 platform. We found microRNA expression profiles significantly associated with lung cancer and that these microRNAs target mRNA whose expression was previously reported to be associated with lung cancer. Importantly, we show that integrating microRNA expression together with a gene-expression lung cancer biomarker increases performance.

9:30 スポンサー提供のプレゼンテーション (講演者を募集しています)

9:45 展示会ホールでの休憩、ポスター発表の見学


がんの経路におけるマイクロRNAの役割

10:25 議長の発言

Richard I. Gregory, Ph.D., Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, Department of Pediatrics, Harvard Medical School, Harvard Stem Cell Institute, The Stem Cell Program at Boston Children's Hospital

10:30 転移性メラノーマでのマイクロRNAの予測面と機能面の役割

Eva Hernando, Ph.D., Associate Professor and Vice Chair for Science, Department of Pathology; Co-Leader, Melanoma Program, NYU Langone Medical Center

Our laboratory has identified a miRNA signature in primary melanomas predictive of recurrence and metastasis. We have also demonstrated that some components of that signature which are lost in aggressive primary tumors act as metastasis suppressors. Our data supports that a miRNA-based prognostic assay could identify patients at higher risk of developing metastatic disease who could be subjected to increased surveillance or adjuvant therapies. Moreover our results support that miRNA changes can capture the molecular heterogeneity that dictates metastatic behavior since early tumor stages.

11:00 がんのマイクロRNA生合成経路

Richard I. Gregory, Ph.D., Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, Department of Pediatrics, Harvard Medical School, Harvard Stem Cell Institute, The Stem Cell Program at Boston Children's Hospital

Amplification and overexpression of individual 'oncomiRs' or genetic loss of tumor suppressor miRNAs promotes tumorigenesis. Furthermore, global miRNA depletion caused by genetic and epigenetic alterations in components of the miRNA biogenesis machinery is oncogenic. This, together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer.

11:30 Smad2と自食作用を通じたmiR-140による大腸がん幹細胞の除去

Jingfang Ju, Ph.D., Associate Professor and Co-Director, Translational Research, Pathology, Stony Brook University

Colorectal cancer (CRC) is the third highest mortality cancer in the US and frequently metastasizes to liver and lung. Smad2 is a key element downstream of the TGF-β signaling pathway to regulate cancer metastasis by promoting epithelial to mesenchymal transition and maintaining the cancer stem cell (CSC) phenotype. In this study, we show that hsa-miR-140-5p directly targets Smad2 and overexpression of hsa-miR-140-5p in CRC cell lines decreases Smad2 expression levels, leading to decreased cell invasion and proliferation, and increasing cell cycle arrest. The functional and clinical significance of hsa-miR-140-5p suggests that it is a key regulator in CRC progression and metastasis, and may have potential as a novel therapeutic molecule to treat CRC.

12:00 学会閉幕



1日目 | 2日目

* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。


Choose your language
Traditional Chinese
Simplified Chinese
Korean
English


View Media Partners


Catalog

 
イベントカレンダー
医薬品関連の国際会議

CHI | Cambridge HealthTech Institute
日本語公式サイト運営 : Cambridge HealthTech Institute代理店 株式会社グローバル インフォメーション